The synthesis of azapeptidomimetic β-lactam molecules as potential protease inhibitors

Journal of Organic Chemistry

Volumn 67, Issue 25, 2002, Pages 8962-8969

  Malachowski, William P ^a   Tie, Chenyang ^b   Wang, Katherine ^b   Broadrup, Robert L ^b  

^a UNIVERSITY OF NEW ENGLAND   (United States)

^b BRYN MAWR COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

STRUCTURE (COMPOSITION); SUBSTRATES; SYNTHESIS (CHEMICAL);

PEPTIDE BACKBONE;

ENZYME INHIBITION;

AZAPEPTIDE DERIVATIVE; AZAPEPTIDOMIMETIC BETA LACTAM; BETA LACTAM DERIVATIVE; PROTEINASE INHIBITOR; SERINE; THREONINE; UNCLASSIFIED DRUG; BETA LACTAM; HETEROCYCLIC COMPOUND; OLIGOPEPTIDE; SERINE PROTEINASE INHIBITOR;

ARTICLE; CHEMICAL REACTION; DRUG BINDING; DRUG DESIGN; DRUG STRUCTURE; DRUG SYNTHESIS; MITSUNOBU REACTION; BINDING COMPETITION; BINDING SITE; CATALYSIS; CHEMICAL STRUCTURE; CHEMISTRY; COMBINATORIAL CHEMISTRY; ENZYME SPECIFICITY; MOLECULAR MIMICRY; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

AZA COMPOUNDS; BETA-LACTAMS; BINDING SITES; BINDING, COMPETITIVE; CATALYSIS; COMBINATORIAL CHEMISTRY TECHNIQUES; DRUG DESIGN; MODELS, MOLECULAR; MOLECULAR MIMICRY; MOLECULAR STRUCTURE; OLIGOPEPTIDES; SERINE PROTEINASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY;

EID: 0037073813     PISSN: 00223263     EISSN: None     Source Type: Journal    
DOI: 10.1021/jo026280d     Document Type: Article

References (74)

1. For reviews on peptidomimetic enzyme inhibitors, see: (a) Babine, R. E.; Bender, S. L. Chem. Rev. 1997, 97, 1359. (b) Leung, D.; Abbenante, G.; Fairlie, D. P. J. Med. Chem. 2000, 43, 305. (c) Whittaker, M.; Floyd, C. D.; Brown, P.; Gearing, A. J. H. Chem. Rev. 1999, 99, 2735. (d) Otto, H.-H.; Schirmeister, T. Chem. Rev. 1997, 97, 133.
2. For reviews on peptidomimetic enzyme inhibitors, see: (a) Babine, R. E.; Bender, S. L. Chem. Rev. 1997, 97, 1359. (b) Leung, D.; Abbenante, G.; Fairlie, D. P. J. Med. Chem. 2000, 43, 305. (c) Whittaker, M.; Floyd, C. D.; Brown, P.; Gearing, A. J. H. Chem. Rev. 1999, 99, 2735. (d) Otto, H.-H.; Schirmeister, T. Chem. Rev. 1997, 97, 133.
3. For reviews on peptidomimetic enzyme inhibitors, see: (a) Babine, R. E.; Bender, S. L. Chem. Rev. 1997, 97, 1359. (b) Leung, D.; Abbenante, G.; Fairlie, D. P. J. Med. Chem. 2000, 43, 305. (c) Whittaker, M.; Floyd, C. D.; Brown, P.; Gearing, A. J. H. Chem. Rev. 1999, 99, 2735. (d) Otto, H.-H.; Schirmeister, T. Chem. Rev. 1997, 97, 133.
4. For reviews on peptidomimetic enzyme inhibitors, see: (a) Babine, R. E.; Bender, S. L. Chem. Rev. 1997, 97, 1359. (b) Leung, D.; Abbenante, G.; Fairlie, D. P. J. Med. Chem. 2000, 43, 305. (c) Whittaker, M.; Floyd, C. D.; Brown, P.; Gearing, A. J. H. Chem. Rev. 1999, 99, 2735. (d) Otto, H.-H.; Schirmeister, T. Chem. Rev. 1997, 97, 133.
5. 1.
6. (a) Scrimager, S. T.; Hofmann, T. J. Biol. Chem. 1967, 242, 2528-2533.
7. (b) Schechter, I.; Berger A. Biochem. Biophys. Res. Commun. 1967, 27, 157.
8. (c) Abramowitz, N.; Schechter, I.; Berger, A. Biochem. Biophys. Res. Commun. 1967, 29, 862
9. (d) Atlas, D.; Levit, S.; Schechter, I.; Berger, A. FEBS Lett. 1970, 11, 281.
10. (a) Imperiali, B.; Abeles, R. H. Biochemistry 1987, 26, 4474.
11. (b) Baggio, R.; Shi, Y.-Q.; Wu, Y.-q.; Abeles, R. H. Biochemistry 1996, 35, 3351.
12. (c) Mookhtiar, K. A.; Marlowe, C. K.; Bartlett, P. A.; Van Wart, H. E. Biochemistry 1987, 26, 1962.
13. (d) Hu, L.-Y.; Abeles, R. H. Arch. Biochem. Biophys. 1990, 281, 271.
14. (e) Abato, P.; Conroy, J. L.; Seto, C. T. J. Med. Chem. 1999, 42, 4001.
15. (f) Chatterjee, S.; Dunn, D.; Tao, M.; Welb, G.; Gu, Z.-Q.; Bihovsky, R.; Ator, M. A.; Simon, R.; Mallamo, J. P. Bioorg. Med. Chem. Lett. 1999, 9, 2371.
16. (g) Yamashita, D. S.; Smith, W. W.; Zhao, B.; Janson, C. A.; Tomaszek, T. A.; Bossard, M. J.; Levy, M. A.; Oh, H.-J.; Carl, T. J.; Thompson, S. K.; Ijames, C. F.; Carr, S. A.; McQueney, M.; D'Alessio, K. J.; Amegadzie, B. Y.; Hanning, C. R.; Abdel-Meguid, S.; DesJarlais, R. L.; Gleason, J. G.; Veber, D. F. J. Am. Chem. Soc. 1997, 119, 11351.
17. (a) Umezawa, H.; Aoyagi, T.; Morishima, H.; Kunimoto, S.; Matsuzaki, M.; Hamada, M.; Takeuchi, T. J. Antibiot. 1970, 23, 425.
18. (b) Verstraete, M. Haemostasis 1996, 26, 70.
19. Kettner, C. A.; Shenvi, A. B. J. Bio. Chem. 1984, 259, 15106.
20. (b) Quan, M. L.; Wityak, J.; Dominguez, C.; Duncia, J. V.; Kettner, C. A.; Ellis, C. D.; Liauw, A. Y.; Park, J. M.; Santella, J. B.; Knabb, R. M.; Thoolen, M. J.; Weber, P. C.; Wexler, R. R. Bioorg. Med. Chem. Lett. 1997, 7, 1595.
21. (a) Powers, J. C.; Gupton, B. F.; Harley, A. D.; Nishino, N.; Whitley, R. J. Biochim. Biophys. Acta 1977, 485, 156.
22. (b) Bode, W.; Turk, D.; Karshikov, A. Protein Sci. 1992, 1, 426.
23. (a) Imperiali, B.; Abeles, R. H. Biochemistry 1986, 25, 3760.
24. (b) Veale, C. A.; Bernstein, P. R.; Bohnert, C. M.; Brown, F. J.; Bryant, C.; Damewood, J. R., Jr.; Earley, R.; Feeney, S. W.; Edwards, P. D.; Gomes, B.; Hulsizer, J. M.; Kosmider, B. J.; Krell, R. D.; Moore, G.; Salcedo, T. W.; Shaw, A.; Silberstein, D. S.; Steelman, G. B.; Stein, M.; Strimpler, A.; Thomas, R. M.; Vacek, E. P.; Williams, J. C.; Wolanin, D. J.; Woolson, S. J. Med. Chem. 1997, 40, 3173.
25. (a) Firestone, R. A.; Barker, P. L.; Pisano, J. M.; Ashe, B. M.; Dahlgren, M. E. Tetrahedron 1990, 46, 2255.
26. (b) Knight, W. B.; Chabin, R.; Green, B. Arch. Biochem. Biophys. 1992, 296, 704.
27. (c) Yoakim, C.; Ogilvie, W. W.; Cameron, D. R.; Chabot, C.; Guse, I.; Hache, B.; Naud, J.; O'Meara, J. A.; Plante, R.; Deziel, R. J. Med. Chem. 1989, 32, 2882.
28. (d) Bulychev, A.; O'Brien, M. E.; Massova, I.; Teng, M.; Gibson, T. A.; Miller, M. J.; Mobashery, S. J. Am. Chem. Soc. 1995, 117, 5938.
29. (e) Kuo, D.; Weidner, J.; Griffin, P.; Shah, S. K.; Knight, W. B. Biochemistry 1994, 33, 8347.
30. (f) Achilles, K.; Schneider, M.; Schirmeister, T.; Otto, H.-H. Pharmazie 2000, 55 (11), 798.
31. (g) Achilles, K.; Schirmeister, T.; Otto, H.-H. Arch. Pharm. 2000, 333 (8), 243.
32. Skiles, J.; McNeil, D. Tetrahedront. Lett. 1990, 31, 7277.
33. (a) Neumann, U.; Steinmetzer, T.; Barth, A.; Demut, H. U. J. Enzymol. Inhib. 1991, 4, 213.
34. (b) Powers, J. C.; Boone, R.; Carroll, D. L.; Gupton, B. F.; Kam, C.-M.; Nishino, N.; Sakamoto, M.; Tuhy, P. M. J. Biol. Chem. 1984, 259, 4288.
35. (c) Gupton, B. F.; Carroll, D. L.; Tuhy, P. M.; Kam, C.-M.; Powers, J. C. J. Biol. Chem. 1984, 259, 4279.
36. (d) Dorn, C. P.; Zimmerman, M.; Yang, S. S.; Yurewicz, E. C.; Ashe, B. M.; Frankshun, R.; Jones, H. J. Med. Chem. 1977, 20, 1464.
37. (e) Gray, C. J.; Al-Dulaimi, K.; Khoujah, A. M.; Parker, R. C. Tetrahedron 1977, 33, 837.
38. (f) Barker, S. A.; Gray, C. J.; Ireson, J. C.; Parker, R. C.; McLaren, J. V. Biochem. J. 1974, 139, 555.
39. (g) Powers, J. C.; Gupton, B. F. Methods Enzymol. 1977, 46, 208.
40. (a) Xing, R.; Hanzlik, R. P. J. Med. Chem. 1998, 41, 1344.
41. (b) Magrath, J.; Abeles, R. H. J. Med. Chem. 1992, 35, 4279. See also ref 4b.
42. (a) Atherton, F. R.; Lambert, R. W. Tetrahedron 1983, 39, 2599.
43. (b) Curran, W. V.; Ross, A. A.; Lee, V. J. J. Antibiotics 1988, 41, 1418.
44. (c) Iwagami, H.; Yasuda, N. Heterocycles 1990, 31, 529.
45. a value is due to the polar effect of the α-nitrogen and is significant enough that the dialkylhydrazinodicarboxylate anion can deprotonate the amide nitrogen creating a strong nucleophile. Miller and co-workers have elegantly illustrated and exploited this fact with related acyl hydroxamate compounds. See: Miller, M. J. Acc. Chem. Res. 1986, 19, 49.
46. (a) Hart, D.; Ha, D.-C. Chem. Rev. 1989, 89, 1447.
47. (b) Brown, M. J. Heterocycles 1989, 29, 2225.
48. Georg, G. I.; Ravikumar, V. T. In The Organic Chemistry of β-Lactams; Georg, G. I., Ed.; VCH Publishers: New York, 1993; Chapter 6.
49. One notable exception: Overman, L. E.; Osawa, T. J. Am. Chem. Soc. 1985, 107, 1698.
50. (a) Palomo, C.; Aizpurua, J. M.; Benito, A.; Galarza, R.; Khamrai, U. K.; Vazquez, J.; de Pascual-Teresa, B.; Nieto, P. M.; Linden, A. Angew. Chem., Int. Ed. 1999, 38, 3056.
51. (b) Linder, M. R.; Podlech, J. Org. Lett. 1999, 1, 869.
52. (c) Maier, T. C.; Frey, W. U.; Podlech, J. Eur. J. Org. Chem. 2002, 2686.
53. (d) Sreenivasan, U.; Mishra, R. K.; Johnson, R. L. J. Med. Chem. 1993, 36, 256.
54. (a) Karle, I. Acc. Chem. Res. 1999, 32, 693.
55. (b) Venkatraman, J.; Shankaramma, S. C.; Balaram, P. Chem. Rev. 2001, 101, 3131.
56. Koshland, D. E. Proc. Natl. Acad. Sci. U.S.A. 1958, 44, 98.
57. (a) Ma, B. Y.; Shatsky, M.; Wolfson, H. J.; Nussinov, R. Protein Sci. 2002, 11, 184.
58. (b) Bursavich, M. G.; Rich, D. H. J. Med. Chem. 2002, 45, 541.
59. Giegy, J. R. Monosubstituted Hydrazines. Swiss Patent 307,629, Aug. 16, 1955; Chem. Abstr. 1957, 51, 3113f.
60. Giegy, J. R. Monosubstituted Hydrazines. Swiss Patent 307,629, Aug. 16, 1955; Chem. Abstr. 1957, 51, 3113f.
61. (a) Belleau, B.; Malek, G. J. Am. Chem. Soc. 1968, 90, 1651.
62. (b) Kiso, Y.; Yajima, H. J. Chem. Soc., Chem. Commun. 1972, 942.
63. Abbreviations: EDC, 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride; BOP, benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate.
64. (a) Mitsunobu, O. Synthesis 1981, 1.
65. (b) Hughes, D. L. Org. React. 1992, 42, 337.
66. The two-step procedure has been used as an alternative to Mitsunobu conditions for serine hydroxamate cyclization to a β-lactam. See: Floyd, D. M.; Fritz, A. W.; Cimarusti, C. M. J. Org. Chem. 1982, 47, 176.
67. Based on literature precedent with the Mitsunobu reaction of acyl hydroxamates (see: Miller, M. J.; Mattingly, P. G.; Morrison, M. A.; Kerwin, J. F., Jr. J. Am. Chem. Soc. 1980, 102, 7026), the β-carbon of L-threonine should undergo inversion of configuration. However, the stereochemistry at C-4 of the azetidinone in 21 could not be determined due to spectral broadening from rotamers.
68. (a) Nowick, J. S.; Powell, N. A.; Nguyen, T. M.; Noronha, G. J. Org. Chem. 1992, 57, 7364.
69. (b) Tsai, J. H.; Takaoka, L. R.; Powell, N. A.; Nowick, J. S. Org. Synth. 2000, 78, 220.
70. Mattiingly, P. G.; Miller, M. J. J. Org. Chem. 1981, 46, 1557.
71. Coupling reagent abbreviations: EEDQ, 2-ethoxy-1-ethoxycarbonyl-1,2-dihydroquinoline; HOBt, 1-hydroxybenzotriazole hydrate; PyBOP, benzotriazol-1-yl-N-oxy-tris(dimethylamino)phosphonium hexafluorophosphate; HATU, N-[(dimethylamino)-1H-1,2,3- triazolo[4,5-b]-pyridino-1-ylmethylene]-N-methylmethanaminium hexafluorophosphate N-oxide; i-BCF, isobutylchloroformate.
72. (a) Nowick, J. S.; Holmes, D. L.; Noronha, G.; Smith, E. M.; Nguyen, T. M.; Huang, S.-L. J. Org. Chem. 1996, 61, 3929.
73. (b) Nowick, J.S.; Holmes, D. L.; Noronha, G.; Smith, E. M.; Nguyen, T. M.; Huang, S.-L.; Wang, E. H. J. Org. Chem. 1998, 63, 9144.
74. Brosse, N.; Pinto, M.-F.; Jamart-Gregoire, B. J. Org. Chem. 2000, 65, 4370.